Add Yahoo as a preferred source to see more of our stories on Google. Tumors positive for estrogen receptors are the most common subtype of breast cancer. (Douglas Olivares via Getty Images) This ...

The PROTAC market is experiencing rapid growth, driven by rising interest in targeted protein degradation as a next-generation therapeutic approach. Expanding oncology pipelines with drugs in clinical ...

Arvinas (NASDAQ:ARVN) continues to gain attention in Nasdaq Futures, advancing in targeted protein degradation therapies for ...

Inside your body, countless processes are happening every second to keep you alive. Among them is a little-known but powerful protein called CD36. Scientists have just discovered that this protein ...

AI Designs a Novel PROTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its ...

Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

Arvinas plans Phase 3 trials for vepdegestrant combinations in breast cancer and initiates trials for new Parkinson's disease treatments. Arvinas, Inc. announced its plans to begin two Phase 3 ...

A new discovery could pave the way for more effective cancer treatment by helping certain drugs work better inside the body. Scientists at Duke University School of Medicine, University of Texas ...

Targeted protein degradation is a therapeutic strategy that utilizes the cell’s natural machinery to eliminate disease-causing proteins. The field traces its origins to the development of thalidomide ...